Compare SNGX & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | ONFO |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 202.8K |
| IPO Year | 2006 | 2022 |
| Metric | SNGX | ONFO |
|---|---|---|
| Price | $0.38 | $0.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 225.7K | 165.5K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $119,371.00 | ★ $10,730,218.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.48 |
| 52 Week Low | $0.28 | $0.04 |
| 52 Week High | $1.97 | $6.08 |
| Indicator | SNGX | ONFO |
|---|---|---|
| Relative Strength Index (RSI) | 54.97 | 40.53 |
| Support Level | $0.35 | $0.60 |
| Resistance Level | $0.42 | $0.85 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 66.67 | 14.39 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Pace Generative.